gajananmnm
10+ Views

Heart Pump Device Market - Comprehensive Research Including Top Key Players

According to the new market research report Heart Pump Device Market by Product (Ventricular Assist Devices (LVAD, RVAD, BiVAD, and pVAD), Intra-aortic Balloon Pumps, TAH), Type (Extracorporeal and Implantable Pumps), Therapy (Bridge-to-transplant, Destination Therapy) – Global Forecast to 2026″, published by MarketsandMarkets™, the global market is projected to reach USD 5.5 billion by 2026 from USD 2.1 billion in 2021, at a CAGR of 21.6% from 2021 to 2026.

Browse in-depth TOC on “Heart Pump Device Market”
132 – Tables
38 – Figures
179 – Pages

Bridge-to-transplant is expected to hold the largest share of the heart pump device market

The growth of this market is driven by increasing investments, funds, and grants for research on heart failure treatment; rising prevalence of cardiovascular diseases; long waiting periods for heart transplants; favorable reimbursements for heart pump devices; and increasing obesity.

Ventricular assist devices are expected to hold the largest share of the heart pump device market.

Based on products, the heart pump devices market is segmented into ventricular assist devices, intra- aortic balloon pumps, and total artificial hearts. Ventricular assist devices are the largest and fastest-growing segment in this market. Growth in this segment can primarily be attributed to technological advancements, the shortage of organ donors, and the increasing prevalence of heart failure globally.

Implantable heart pump devices are expected to hold the largest share of the heart pump device market.

Based on type, the market is segmented into implantable heart pump devices and extracorporeal heart pump devices. In 2020, implantable heart pump devices accounted for the largest share of this market, due to the introduction of innovative products by leading players and the rising need for an efficient solution to manage heart failure.

Bridge-to-transplant is expected to hold the largest share of the heart pump device market.

Based on therapy, the market is segmented into bridge-to-transplant (BTT), bridge-to-candidacy (BTC), destination therapy (DT), and other therapies. In 2020, the BTT segment accounted for the largest share of this market. Growing awareness about transplantation and the availability of VADs for BTT have propelled the growth of this segment.


Europe commanded the largest share of the heart pump device market in 2021.

On the basis of region, segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2020, Europe commanded the largest share of the market. The large share of this market segment can be attributed to the rising adoption of heart pump devices, the high prevalence of CVDs, the growing number of research activities to improve current technologies, and the limited availability of donor hearts for transplants.

The major players operating in this heart pump device market are Abbott Laboratories (US), Abiomed (US), Medtronic (Ireland), Teleflex Incorporated (US), SynCardia Systems (US), Fresenius Medical Care AG & Co. KGaA (Germany), Getinge (Sweden), CardiacAssist, Inc. (US), Berlin Heart (Germany), Jarvik Heart, Inc. (US), CARMAT (France), SENKO MEDICAL INSTRUMENT Mfg. CO., LTD. (Japan), Angiodroid (Italy), CardioDyme (US), and World Heart Corporation (US).
Comment
Suggested
Recent
Cards you may also be interested in
How Impacted COVID-19 on U.S. Shale Gas in Chemical Industry ?
Impact of COVID-19 on U.S. Shale Gas in Chemical Industry INTRODUCTION Shale gas and shale oil are defined as natural gas & oil from shale formations. Shale is a type of sedimentary rock that is made up of very small clay particles and is highly porous in nature. It is formed in deep ocean water, lagoons, wetlands, and swamps where the water is still enough for extremely fine clay and silt particles to settle to the bottom. Since shale is a porous formation, it serves as both a source and a reservoir for unconventional hydrocarbons. The extraction of oil and gas from a shale formation involves mechanical stimulation. One such technique for stimulation is hydraulic fracturing or fracking. In the fracking process, cracks in and below the Earth's surface are opened and widened by injecting water, chemicals, and sand at high pressure. The combination of horizontal drilling and hydraulic fracking has made it possible to access vast quantities of shale gas that were previously uneconomical to generate. Natural gas output from shale deposits has given the United States natural gas industry a new lease on life. The demand for safe access to energy sources is growing globally. Shale oil and gas have played an important role in meeting global energy demand during the energy revolution and are expected to continue to do so for decades as society transitions to lower-carbon energy sources. The rapid growth of shale oil and gas contributes to increased supply stability and lower commodity prices. According to the United States Energy Information Administration (EIA), in the year 2011, the country’s estimated available natural gas resources totaled 2,552 trillion cubic feet (Tcf). Natural gas from shale deposits, which was once considered to be uneconomical, accounted for 827 Tcf of this resource total. In the year 2020, U.S. dry shale gas production was about 26 trillion cubic feet (Tcf), and equal to about 78% of total U.S. dry natural gas production. IMPACT OF COVID-19 ON U.S. SHALE INDUSTRY Shale oil and gas exploration have, in particular, given the US oil and gas industry new dimensions of development. It has also fueled significant investment in associated infrastructure for gathering, storing, and delivering hydrocarbons to both domestic and foreign markets. In less than a decade, the US shale industry turned the global energy landscape upside down and re-established the US as the global energy leader. The onset of a global pandemic and subsequent drop in oil prices, on the other hand, has taken the momentum out of the shale boom. Due to a sudden drop in demand, the shale industry has immediately self-corrected. Many oil and gas players succumbed to the economic shock resulted from the CoVID-19 and filed for bankruptcy. Chesapeake Energy, a shale leader and once second-largest gas producer in the United States, filed for Chapter 11 bankruptcy protection in late June. According to the United States Energy Information Administration (EIA), the crude-oil output from seven major shale formations in the United states fell by around 56,000 barrels per day (BPD) in August 2020 to just under 7.5 million BPD, which would be the lowest level in two years. The shale industry is closely looped in with the oil and gas industry. The recent downfall of the oil and gas industry during the pandemic has had a severe impact on shale output. Post pandemic, the shale industry peaked, but the industry as a whole lost money. Since 2010, the US shale industry has produced USD 300 billion in net negative free cash flows, damaged more than USD 450 billion in invested capital, and seen more than 190 bankruptcies. With the advent of the coronavirus, the future for shale producers has become even bleaker, with a new bankruptcy filing occurring every week or so in the last few months. The pandemic's effects will be felt far beyond the US shale industry. Despite accounting for less than 10% of global oil and gas output, US shale oil extraction activity accounts for 40% of global shale oil extraction activity and accounts for nearly 100% of the growth in US midstream and export-oriented refining and petrochemical sectors over the last decade. STRATEGIC INITIATIVES DURING COVID-19 · Organization of the Petroleum Exporting Countries (OPEC) agreed on a continuation of March production levels for the month of April, with the exception of Russia and Kazakhstan, which will be authorized to increase production by 130,000 and 20,000 barrels per day, respectively, at their most recent meeting · Saudi Arabia has also agreed to extend its one-million-barrel-per-day voluntary cut for the month of April. · Companies such as Chevron, Shell, Schlumberger, and others have taken initiatives to safeguard their workforce in the ongoing pandemic situation. CONCLUSION On Conclusion, the pandemic has placed the shale industry in a delicate spot as major players are forced to cut down the output. The potential energy landscape in the United States and around the world is highly complex, and its drivers are interconnected. In the not-too-distant future, a wave of consolidation in the US shale industry could be triggered by the poor financial position of many firms and the weak economic outlook. The continuous demand for a ban on fracking, coupled with the effect of COVID, has cracked the shale industry severely. Although, the historic evidence indicates that the shale producers operate more economically. In comparison to 2019, producers in the Permian Basin are saving roughly 20% on good costs.
Growth in Stem Cell and Neurobiology Research are Expected in Cell Surface Markers
The largest regional market for cell surface markers is primarily driven by the increasing number of R&D activities and the growing use of cell surface markers in personalized medicine and drug discovery & development. However, the market in Asia is estimated to grow at the highest CAGR during the forecast period. The high growth of the Asian market can be attributed to the increasing number of life sciences research activities and government initiatives to boost the biotechnology and pharmaceutical industries in several Asian countries.  Clinical Applications Segment is Expected to Grow at the Highest CAGR During the Forecast Period Based on application, the cell surface markers market is segmented into research applications and clinical applications. The clinical applications segment is expected to witness higher growth during the forecast period primarily due to the rising prevalence of cancer and the increasing adoption of cell surface markers in cancer treatment. Hospitals & Clinical Testing Laboratories use Cell Surface Markers for the Diagnosis of Various Diseases On the basis of end-user, the cell surface markers market is segmented into academic & research institutes, hospitals & clinical testing laboratories, and pharmaceutical & biotechnology companies. The hospitals & clinical testing laboratories segment is expected to register the highest CAGR during the forecast period. The increasing incidence of chronic diseases such as cancer and HIV is expected to boost the demand for cell surface markers in hospitals & clinical testing laboratories in the coming years. North America is expected to be the largest regional market for cell surface markers in 2018 The global cell surface markers market is segmented into four major regions, namely, North America, Europe, Asia, and the Rest of the World. In 2018, North America is expected to account for the largest share of the market. The large share of the North American market is attributed to factors such as the increasing number of R&D activities and the growing use of cell surface markers in personalized medicine and drug discovery & development.   Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=216278622 Key Market Players The cell surface markers market is highly fragmented in nature, with several big as well as emerging players. Prominent players in this market include Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (US), F. Hoffman-La Roche (Switzerland), Bio-Rad Laboratories (US), Danaher Corporation (US), Abcam (UK), GenScript (China), BioLegend (US), Cell Signaling Technology (US), Merck KGaA (Germany), and Bio-Techne (US). Abcam is one of the prominent players operating in the cell surface markers market. The strong position of the company in this market can be attributed to its robust product portfolio. The company has a strong geographical presence in the European and Asia Pacific markets with its manufacturing facilities in the UK, Japan, and China. The company also has significant market presence in the US and Latin America. Thermo Fisher Scientific is another leading player in the cell surface markers market. The company’s strong brand recognition and extensive product portfolio in this market are its key strengths. To maintain its leading position in the market, the company adopts organic as well as inorganic growth strategies such as acquisitions and expansions.  Research Recent Developments Analysis 1. In 2018, Thermo Fisher Scientific acquired the Advanced Bioprocessing business of Becton, Dickinson and Company. This will be integrated into the Life Sciences Solutions segment of Thermo Fisher. 2. In 2018, Abcam entered into an exclusive license agreement with Roche. Under this agreement, the product portfolio of Spring Bioscience Corporation has been licensed to Abcam for research use only (RUO) applications. 3. In 2018, QIAGEN opened its new shared service center in Manila—QIAGEN Business Services (QBS). QBS will provide services related to supply chain management, customer care, accounting, technical services, and other sales support activities to QIAGEN'S global operations.
Kẹo sâm Hamer tăng cường sinh lý
Kẹo sâm Hamer tăng cường sinh lý nam có tên gọi đầy đủ là Hamer Gingseng & Coffee. Đây là một sản phẩm được nghiên cứu phát triển bởi The Sino-USA Collaboration Technology, hợp tác cùng với trường y tế Alabama University Medical của Mỹ. Kẹo ngậm tăng cường sinh lý Hamer có tác dụng tăng cường cơ thể sản xuất hoóc môn sinh dục, tăng ham muốn, tăng sự kích thích và tăng cường cương dương, từ đó tăng chất lượng cuộc yêu, giúp nam giới khỏe hơn trên giường. Kẹo sâm Hamer là viên ngậm tăng cường sinh lý có hiệu quả nhanh, được nghiên cứu và sản xuất theo tiêu chuẩn về sức khỏe của Mỹ. Sản phẩm có nguồn gốc xuất sứ từ Mỹ nhưng hiện nay đã được chuyển giao quy trình sản xuất sang Malaysia. Kẹo sâm Hamer là sự kết hợp của nhiều thành phần thảo dược như nhân sâm, tinh chất lựu, men vi sinh, mạch nha,.. có công dụng cường dương, tăng thời gian quan hệ, tăng thời gian cương cứng, cho “cậu nhỏ” khả năng dẻo dai, chinh chiến lâu hơn. Hiện nay, sản phẩm kẹo sâm hamer đang được rao bán trên thị trường có 2 nguồn nhập khẩu chính là từ Mỹ và từ Malaysia. Nguồn hàng của Kẹo sâm Hamer có nguồn gốc ban đầu là từ Mỹ. Sau này có sự chuyển giao công nghệ sang Malaysia. Nên hiện nay trên thị trường có 2 loại hamer với nguồn gốc khác nhau. Bạn có thể tham khảo sản phẩm tại https://shopmanplus.com/keo-sam-hamer/ #shopmanplus
Refurbished Medical Equipment Market is Set to $21.2 billion by 2025
The growth of the global refurbished medical equipment market can be attributed to factors such as hospital budget cuts, a large inventory of used or old medical devices, rising demand for capital-intensive diagnostic imaging equipment, e-commerce platform enhancing the ease of purchase of refurbished medical equipment, growing preference for eco-friendly products, an increasing number of diagnostic centers & hospitals, and the growing opportunities in emerging economies.  However, factors such as stringent regulations on the import and use of refurbished medical devices in certain countries, lack in the standardization of policies for the use & sale of refurbished devices, increase in the influx of low-cost new medical devices, and the negative perception about the quality of refurbished medical devices are expected to restrain the market growth. Furthermore, the growth of the market is expected to be slowed temporarily due to the COVID-19 pandemic during the forecast period.  The refurbished medical equipment market is segmented into medical imaging equipment, operating room & surgical equipment, patient monitors, cardiology equipment, urology equipment, neurology equipment, intensive care equipment, endoscopy equipment, IV therapy systems, and other medical equipment.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=770 The rising demand for diagnostic imaging procedures, the high price of new medical imaging equipment, a growing number of target diseases, widening application of diagnostic imaging procedures, regulatory approvals in using refurbished medical equipment, low purchasing power in emerging economies, and established & government validated refurbishment processes adopted by major OEMs are factors expected to drive the growth of this market segment in the coming years.  The hospitals' segment accounted for the largest share of the market in 2019. The rising adoption of refurbished medical equipment, increasing focus of hospitals on providing affordable treatment and care, and growing emphasis on high returns on investment are some of the key factors driving the growth of this market.  The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. This can be attributed to the large patient pool in the region, increasing privatization in the healthcare sector, huge patient population base, and high demand for refurbished medical equipment by low-budget hospitals and clinics.  Research Developments 1. In 2020, Siemens Healthineers (Germany) and Hamilton Health Sciences (Canada) have signed a 15 years contract that can be extended by another 10 years to provide comprehensive services for the latest imaging equipment at Hamilton Health Sciences hospitals in Canada. The deal size was approximately USD 192 million. 2. In 2019, US Med-Equip (US) acquired Medical Support Products (US) to increase the capability, national expansion, and provide greater product and service solutions across the US. 3. In 2019, Avante Health Solutions opened a new Charlotte facility in North Carolina, US. This will house three business divisions of the company viz., Avante Diagnostic Imaging, Avante Oncology, and Avante Ultrasound. 4. In 2018, Koninklijke Philips (Netherlands) acquired AGITO Medical (Denmark), strengthening its refurbished medical equipment portfolio of products, parts, and services. 5. In 2017, US Med-Equip  (US), and the Owner-Research group (US) signed a partnership to augment the economy and medical equipment products and services across hospitals in the US.
Industry Trends, Growth and Analysis For Healthcare Fraud Analytics
Fraud analytics is the efficient use of data analytics and related business insights developed through statistical, quantitative, predictive, comparative, cognitive, and other emerging applied analytical models for detecting and preventing healthcare fraud. The global healthcare fraud analytics market is projected to reach USD 5.0 billion by 2026 from USD 1.5 billion in 2021, at a CAGR of 26.7% during the forecast period. Market growth can be attributed to a large number of fraudulent activities in healthcare, the increasing number of patients seeking health insurance, high returns on investment, and the rising number of pharmacy claims-related frauds. However, the dearth of skilled personnel is expected to restrain the growth of this market.  The global healthcare fraud analytics market is facing a plethora of challenges. Travel bans and quarantines, halt of indoor/outdoor activities, temporary shutdown of business operations, supply-demand fluctuations, stock market volatility, falling business assurance, and many uncertainties are somehow exerting a partial negative impact on the business dynamics.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=221837663 The healthcare industry has been witnessing a number of cases of fraud, done by patients, doctors, physicians, and other medical specialists. Many healthcare providers and specialists have been observed to be engaged in fraudulent activities, for the sake of profit. In the healthcare sector, fraudulent activities done by patients include the fraudulent procurement of sickness certificates, prescription fraud, and evasion of medical charges.  A couple of reasons contributing to the growth of the health insurance market include the rise in the aging population, growth in healthcare expenditure, and increased burden of diseases. In the US, the number of citizens without health insurance has significantly decreased, from 48 million in 2010 to 28.6 million in 2016. In 2017, 12.2 million people signed up for or renewed their health insurance during the 2017 open enrollment period (Source: National Center for Health Statistics).  This growth is aided by the increasing affordability of health insurance for the middle class in this region and the rising awareness regarding the benefits of health insurance. In the UAE, as per a new regulatory policy (2017), any citizen residing and working in the UAE needs to be insured medically.   Major players in this market include IBM Corporation (US), Optum, Inc. (US), Cotiviti, Inc. (US), Change Healthcare (US), Fair Isaac Corporation (US), SAS Institute Inc. (US), EXLService Holdings, Inc. (US), Wipro Limited (India), Conduent, Incorporated (US), CGI Inc. (Canada), HCL Technologies Limited (India), Qlarant, Inc. (US), DXC Technology (US), Northrop Grumman Corporation (US), LexisNexis (US), Healthcare Fraud Shield (US), Sharecare, Inc. (US), FraudLens, Inc. (US), HMS Holding Corp. (US), Codoxo (US), H20.ai (US), Pondera Solutions, Inc. (US), FRISS (The Netherlands), Multiplan (US), FraudScope (US), and OSP Labs (US).  Research Developments Analysis 1. In January 2019, LexisNexis Risk Solutions collaborated with QuadraMed to enable patient identification capabilities and reduce the number of duplicate identities & fraudulent claims. 2. In August 2018, Verscend Technologies acquired Cotiviti Holdings. This acquisition helped improve the affordability of fraud detection solutions. 3. In June 2018, SAS Institute & Prime Therapeutics LLC teamed up, enabling Prime Therapeutics to utilize SAS’s analytic capabilities to combat the opioid crisis in the US
How COVID-19 Impacted on Automated Cell Cultures in Healthcare Industry ?
COVID-19 Impact on Automated Cell Cultures in Healthcare Industry The economy and businesses across the world have been influenced greatly because of the COVID-19 pandemic. The COVID-19 has spread globally in unprecedented ways due to its high infectious and contagious nature and lack of vaccine. The World Health Organization (WHO) declared COVID-19 as a pandemic due to its increased spread across the globe. According to the situation report of 7th June 2021 by WHO, 174 million corona cases had been reported globally and 3.7 million patients died due to the coronavirus. On a slightly positive note, a total of 157 million people have recovered, and 1.9 million vaccine doses have been administered. Cell culture refers to removing cells from an animal or plant and their subsequent growth in a favorable artificial environment. Automated cell culture systems are instruments that mechanically carry out the steps involved in growing and maintaining a cell culture useful in any lab that works with cell biology, cell signaling, protein expression, or drug discovery. An automated cell culture system helps to grow cell cultures while saving labor time and reducing errors. Increasing demand for cell culture technology in vaccine production and wide acceptance of cell culture techniques in various applications accelerate the market growth. However, the high cost of automated cell culture systems and lack of skilled and certified professionals are expected to obstruct the market growth. COVID-19 pandemic created problems for many drug, clinical, medical equipment, and device manufacturing companies, including market players that provided automated cell culture products & services. Though, different kind of policies has been adopted by different companies across the globe for carrying forward the manufacturing processes. PRICE IMPACT COVID-19 claimed a considerable number of lives worldwide, which is a concern in countries with high patient co-payments and an appreciable number of families going into poverty when members become ill. Consequently, there is a need to review prices and availability of pharmaceutical products during the COVID-19 pandemic to provide future direction. The pandemic has impacted on utilization and prices of pertinent medicines and products but moderated by increased scrutiny. Key stakeholder groups can play a role in enhancing evidence-based approaches and reducing inappropriate purchasing in the future. For instance; • The Price of BACTEC FX-40 Automated Blood Culture System manufactured by BD is USD 10,608.08 • The price of Gibco HEPES, a reagent used in cell culture manufactured by Thermo Fisher Scientific, is USD 30.90 Product cost is the major setback for the market as it is expected to decrease the demand due to high costs. As the instruments and consumables related products such as cell counters, reagents, and buffers have high prices, the cost of automated cell cultures can impact the market. IMPACT ON DEMAND Today, most biotechnology products are primarily dependent on the mass culturing of cell lines. Cell cultures have found applications in diverse areas and serve as a model system for numerous research efforts. An increase in funding from the government for cell-based research is significantly triggering the growth of the market. In addition, cell culture techniques are widely used as an alternative to current egg-based strategies for developing cell-based vaccines. Thus, cell culture technology has been widely used in developing U.S. -licensed vaccines such as vaccines against rubella, smallpox, chickenpox, hepatitis, rotavirus, and polio. For instance, • Over the last month and a half, the Centre for Cellular and Molecular Biology has established stable cultures of COVID-19 causing coronavirus. The lab's ability to culture the virus enables CCMB to develop vaccines and test potential drugs to fight COVID-19. As observed, because of the current COVID-19 situation, the demand for automated cell culture services gradually increased due to the wide acceptance of cell culture techniques in various applications and growth in the biotechnology sector. This shows that various initiatives taken by organizations and market players are helping to tackle this COVID-19 situation as products are made available, and the situation is likely to get better in the future. IMPACT ON SUPPLY CHAIN Lockdown policies in different countries have resulted in the closing of product providers, decreasing walk-in customers to prevent the spread of the disease. This led to a significant delay in the supply of the product. Also, during the lockdown period, the market for online delivery of products has seen a rise, which is normal considering the situation. The companies dealing in the automated cell culture worldwide have taken strategic steps to supply products to people across the world properly. The Coronavirus Disease 2019 (COVID-19) pandemic triggered unprecedented increased demand for some clinical devices, as well as significant disruptions to global medical and clinical device manufacturing and supply chain operations. The FDA is monitoring the medical and clinical product supply chain and working closely with manufacturers and other stakeholders to evaluate the risk of disruptions and prevent or reduce their impact on patients, health care providers, and the public's health at large. For instance, · On March 27th 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was signed into law. The CARES Act added Section 506J to the Federal Food, Drug, and Cosmetic Act (FD&C Act). It provided the FDA—for the first time—with new authority intended to help prevent or mitigate negative public health impacts of medical device supply chain disruptions “during, or in advance of, a public health emergency declared by the Secretary under section 319 of the Public Health Service (PHS) Act.” The FDA issued an immediately in effect guidance, Notifying CDRH of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the FD&C Act During the COVID-19 Public Health Emergency: Guidance for Industry and Food and Drug Administration Staff. This guidance is intended to assist manufacturers in providing the FDA timely, informative notifications about changes in the production of certain medical devices that will help the Agency prevent or mitigate shortages of such devices during the COVID-19 public health emergency. · In April 2020, according to Indian Drug Manufacturers Association (IDMA), Vice-Chairman, T Sathish, the pharma sector in the country has been hit by a shortage of workforce, packaging materials, and transport the COVID-19 lockdown. This has led to a shortage of product packaging materials and has made matters worse for the pharmaceutical companies. He urged the government to permit the supporting industry to function to ensure that the supply chain was not disrupted. This shows that even if the COVID-19 situation disrupts the supply chain of products, the initiatives taken by the government and different companies create hope for the proper supply and use of products available. STRATEGIC DECISIONS FOR MANUFACTURERS COVID-19 might have hampered the supply and use of products, but it also allows companies to improve their business by different means. As a pharmaceutical company always does, it tends to find newer and better ways to treat a disease; the same is true with automated cell culture services and products. Always bringing out better solutions in the market will increase their business efficiency. For instance, · In 2020, in the U.S., the companies with direct exposure to COVID-19 outbreak were taking several actions, including transporting available inventory to areas away from quarantine zones and near ports where it can be accessed for shipping, buying ahead to procure inventory and raw material that are in short supply in impacted areas, activating pre-approved raw material substitutions in places where the primary supplier is impacted. However, a secondary supplier is not updating customers about delays and adjusting customer allocations to optimize profits on near-term revenue or to meet contractual terms and shaping demand by offering a discount on the available inventory in cases where supply may be short for late winter-early spring fulfillment optimizing near-term revenue. This signifies that despite this COVID-19 situation, the companies make different strategic decisions that will make their business grow at least back to pre-pandemic levels. CONCLUSION Pandemic has taken a toll on every aspect of life, including the global economy. With the significant downfalls in many sectors, a collaborative effort of government, industry players, and consumers can win the fight against COVID-19. The first wave had already inflicted severe blows to the population and economy. The currently experiencing the second wave and expected the third wave is likely to be more disastrous to the masses and healthcare markets. As this pandemic situation has resulted in many restrictions in different places around the world, the market players dealing in automated cell culture services and products were still able to manage their stock. Different companies were finding out their way to deal with this pandemic situation. The government and companies around the globe are working together and have issued advice for those who are undergoing treatment during these unprecedented times during COVID-19 lockdown around the world. The supply chain was destroyed, but several steps were taken by the government and companies, which will help them get their needed output for the products. By increasing the material price, the companies can maintain their overall revenue. Thus, different companies dealing in automated cell culture services and products are finding out their ways to deal with this pandemic situation.
Cell-based Assays Market Expected to Reach $22.0 billion by 2025
The growing preference for cell-based assays in drug discovery, increasing funding for cell-based research, and growth in the number of drug discovery activities are the key factors supporting the growth of the market.   The cell-based assays market is projected to reach USD 22.0 billion by 2025 from USD 14.9 billion in 2020, at a CAGR of 8.1% during the forecast period. However, the growth of the market is likely to be restrained by factors such as the high cost of instruments, restrictions on reagent use, and the lack of infrastructure for cell-based research in emerging economies.  Due to the pandemic, companies have scaled up R&D efforts to develop a vaccine and drugs against the SARS-CoV-2 virus. Vaccine-related research activities in pharmaceutical & biotechnological companies, research centers, and academic research institutes are considered essential and have been largely unaffected in operations and output.  The players operating in the market are altering their long-term and short-term growth strategies by tapping into opportunities prevalent in the research market by developing innovative products to combat the pandemic. The increased demand for research on COVID-19 has created a large scope for cell-based 45 assays in viral infection research, vaccine development, and overall drug discovery for both researchers and laboratories.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=119917269 Cell-based assays are employed to shorten the time and increase the throughput needed for these assays. This has significantly increased the demand for cell-based assays to provide an early indication of the toxicity characteristics of the drug candidates.  Cell-based assays are key components in the drug development process. Cell-based assays have several advantages over in vitro biochemical assays. They offer consistent tissue-specific responses in a biologically relevant microenvironment as opposed to biochemical assays.  It is also not possible to prepare or purify every target for biochemical measurement, which is a major factor limiting the applications of biochemical assays. As a result, pharmaceutical & biotechnology companies as well as CROs are replacing biochemical assays with cell-based assays for their lead identification and optimization processes in drug discovery.  The prominent players operating in the cell-based assays market are Danaher Corporation (US), Thermo Fisher Scientific (US), Merck KGaA (Germany), Becton, Dickinson and Company (US).  Research Developments Analysis 1. In 2020, Danaher Corporation (US) launched ImageXpress Micro-confocal High-content Imaging System. 2. In 2020, Thermo Fisher Scientific (US) acquired Phitonex, Inc. (US). The acquisition of spectral dye platform manufacturer Phitonex will enable Thermo Fisher to offer greater flow cytometry and imaging multiplexing capabilities in protein and cell analysis research. 3. In 2020, Charles River Laboratories entered into a multi-year drug discovery collaboration with Karuna Therapeutics, a US-based CRO, to expand its drug discovery capabilities. 4. In 2020, Danaher Corporation completed the acquisition of GE Healthcare’s biopharma business and was renamed as Cytiva. 5. In 2018, Lonza Group AG (Switzerland) established its Collaborative Innovation Center in the new Life Science Park on the outskirts of Haifa, Israel. This center focuses on the R&D projects of Lonza’s Pharma Biotech & Nutrition segment.
Why You Need A Niacinamide Serum? And How To Use It.
Niacinamide may not get as much attention as retinol and vitamin C, but it is a skincare powerhouse that deserves equal recognition. It is the definition of a multitasker, offering a host of distinct benefits that make it a good choice for a wide range of skin types and complexion issues. However, incorporating it into your current skincare routine might sound difficult. Is it OK to use niacinamide along with vitamin C and/or retinol? Is hyaluronic acid a viable alternative? We weigh in on everything you need to know about using niacinamide. What is niacinamide, exactly? Simply put, it's a B vitamin, one of two forms of vitamin B3, and it participates in a number of critical cellular operations in the skin. What benefits does it have for the skin? Buckle your seatbelts, because this is going to be a long list. Niacinamide is a fantastic treatment for acne-prone skin. Niacinamide reduces sebum production, which can help prevent acne and shine. The vitamin is also known for its anti-inflammatory qualities, which aid in the treatment of acne and other skin conditions such as eczema. Niacinamide helps to build the skin barrier, which is advantageous to people who have eczema or sensitive skin. It is also an efficient skin lightening agent, treating hyperpigmentation by blocking pigment transfer from pigment-producing cells known as melanocytes to skin cells on the surface where discoloration is visible. As if that wasn't enough, there's evidence that niacinamide can help to reduce wrinkling and photoaging by maintaining cell function and repairing DNA damage. To summarise, niacinamide has very few limitations. Is it OK to mix niacinamde and retinol? Yes! In fact, retinol and niacinamide are recommended together for faster effects. The soothing characteristics of niacinamide can also assist to alleviate the unpleasant side effects and irritation that usually accompany retinol's wrinkle-fighting effectiveness. Is it safe to combine with other ingredients? Yes, as a general rule, which is why it's found in many skincare products and is easy to incorporate into your present routine. Niacinamide is frequently coupled with salicylic acid, a beta-hydroxy acid typically found in acne products, due to its acne-fighting qualities. Combining niacinimadie's oil-removal properties with salicylic acid's ability to break down excess oil is an effective way to keep pores free and breakouts at bay. Niacinamide is an ideal choice for combining with alpha-hydroxy acids, which are chemical exfoliants that can cause skin irritation, due to its anti-inflammatory and skin barrier-strengthening effects. Because the AHAs exfoliate the dead skin cells that would otherwise make it impossible for the niacinamide to enter, combining them boosts the efficacy of the niacinamide. Finally, because niacinamide and hyaluronic acid can both help with dry skin, they are frequently mixed. What is the one thing that the jury is still out on? Vitamin C. Because vitamin C might inactivate niacinamide, the applications should be separated by 15 minutes. In truth, the two would have to be heated in order to interact negatively, and more and more cosmetics are combining the two in skin-brightening formulations. The bottom conclusion is that if you utilise a product that contains both vitamin C and niacinamide, it was most likely specifically designed to work together. If you're using two different products that include these chemicals, wait 15 minutes between applications or use one in the morning and the other in the evening. Should I use niacinamide? Sure, in a nutshell. One of the nicest aspects of niacinamide is not only the vast list of benefits it offers, but also how well it is tolerated, particularly by those with sensitive skin. This makes it an enticing choice for those whose skin is sensitive to more common acne or skin lightening agents like benzoyl peroxide or retinoids.
How COVID-19 Impacted on Aluminum Casting in Chemicals & Materials Industry ?
COVID-19 Impact on Aluminum Casting in Chemicals and Materials Industry Aluminum casting refers to the type of metalworking process which consists of the involvement of pouring liquid metal into the mold or in any specific form. They are mainly used in the manufacturing of complex as well as detailed parts efficiently. It only uses aluminum or aluminum alloys as liquid metal which is poured into molds. The usage of aluminum casting ranges from the automotive sector, building & construction, among others. Its usage in car engines as well as in other car-related cast products has been considered to be the biggest consumer of aluminum casting products. Due to the COVID-19, the automotive, building, and construction industry along with other industrial activities has witnessed a slowdown especially in the second quarter of the year 2020. The slowdown started with the US-China trade war and accelerated with the spread of coronavirus. The automotive industry involves a variety of materials that involve the usage of aluminum casting in which various products are produced from a variety of processes. Thus, any impact on the automotive industry has a direct impact on the demand for aluminum casting products. The domestic aluminum casting product makers are suffering from lower profit margins and are worried that their margins will face more dip in the future if the lockdown again happens. Thus, because of the outbreak of COVID-19, the global market for aluminum casting has slowed down and can only recover if the parallel industries such as building, construction, and automotive industry will be on track. AFTERMATH OF COVID-19 AND GOVERNMENT INITIATIVE TO BOOST THE GLOBAL ALUMINUM CASTING MARKET The first and foremost step that the government is planning to take towards the comeback of the aluminum casting industry on track is to make the automotive making industry less dependent on imports. The government has taken various measures to maintain the demand and supply of materials. It is supporting the local producers of aluminum casting and intermediates which are involved in the production of the aluminum casting. For this, the government has decided to extend financial and procedural support to domestic companies to kick start local production. The government is considering various stimulus packages to boost the materials. Along with that to cope with the situation, the government is planning to provide some fiscal initiatives to manufacturers including tax cuts and exemptions, to recover from the disruption. STRATEGIC DECISIONS FOR MANUFACTURERS AFTER COVID-19 TO GAIN COMPETITIVE MARKET SHARE The breakout of coronavirus has shaken the entire industry. Due to this pandemic, most of the production got hit and has created a situation of panic in the entire world. Thus, to maintain the demand and supply various strategic decisions are taken for the manufacturers. The availability of raw materials at a reasonable rate will help manufacturers to obtain raw materials at a much lower cost and can save huge amounts of loss incurs to them. Along with that, the manufacturers try to divide the risk of dependency by involving more than one supplier in any dealing. Also, the government of various countries has extended support to small and medium enterprises so that dependence on imports can be reduced, and domestic demand can be catered to domestically. IMPACT ON PRICE Due to COVID-19 and other macroeconomic events, the supply chain of aluminum casting materials has seen disruption among various manufacturing sectors. This disruption has led to unforeseen price volatility and has also reduced negotiation potential for prospective buyers. The price of aluminum casting and related products is continuously decreasing since the outbreak of coronavirus has incurred in the economy. The construction materials are also witnessing a dip in the pricing and are expecting a hike by the end of the year 2020 like before. The hike in automotive materials pricing may increase the price of aluminum casting materials and may also help manufacturers in maintaining their profit margins. IMPACT ON DEMAND Aluminum casting has witnessed a dip in the demand in various regions due to weak requirements from end-user in the industry especially automotive, building & construction, and in several other industries. Due to the economic and infrastructural slow down the demand for construction materials, especially from building & construction, has decreased which eventually has reduced the consumption of the advanced materials used in them. The decline in various manufacturing sectors due to lockdown & limited working labor has affected the demand among end-users of the market and impacted the overall demand. IMPACT ON SUPPLY CHAIN Due to the outbreak of COVID-19, the supply chain has suffered abruptly. Manufacturers have stock but they are not getting demand for it. So, there is a situation of oversupply in the market. In this situation, both manufacturers and consumers are facing the timely availability of raw materials. The restriction over transportation and labor availability is another factor that has affected the supply chain of aluminum casting. At several parts, the manufacturers are struggling for raw material reach and at the same time, some are struggling with delivering the product. Thus, the impact on supply is not due to one factor but is facing a hit from manufacturing points. CONCLUSION The unfortunate event has led to a disturbance in the availability and the pricing of aluminum casting. Though the imbalance between demand and supply and its impact on pricing is considered to be short-term, it will not have a long-term impact on price. Due to the weak production of aluminum casting products throughout the globe, the demand for aluminum casting has gone down tremendously, with a continuous drop in demand among end-users in the market. Though, the government is taking steps such as relaxation on tax, fiscal deficit, and others to minimize the impact.
Jasa Pengiriman Bandung Bireun, Aceh (0816267079)
Logistik Express Jasa Pengiriman Bandung Bireun, Aceh merupakan jasa pengiriman barang dan cargo dari Bandung ke seluruh Indonesia. Logistik Express didukung oleh team operasional lapangan yang handal, customer service profesional, serta armada darat, laut, maupun udara yang memadai. Sehingga menjadikan Logistik Express sebagai jasa kirim yang aman sampai ke alamat tujuan. Bagi customer tidak perlu khawatir akan proses booking pengiriman yang rumit, karena cukup dengan menghubungi customer service maka barang kiriman anda langsung bisa di proses oleh team kami. Logistik Express juga dilengkapi dengan tracking website, sehingga pengiriman transparan dan mudah dilacak keberadaannya oleh customer. Jasa Kirim Ke Bireun, Aceh dari LogistikExpress.ID temukan harga terbaik untuk pengiriman Express di tempat kami yang telah berpengalaman dan pastinya barang anda aman sampai di tempat tujuan. Harga Tarif  hanya Rp9.000/Kg minimal pengiriman 100Kg Tarif Termurah Di Jasa Pengiriman Online Terbaru Dan Terupdate sampai 2021 di LogistikExpress.ID . LogistikExpress.ID adalah Jasa Pengiriman yang melayani pengiriman ke Seluruh wilayah Indonesia Layanan Customer Service & Order : +62816267079 Cek Tarif pengiriman dari Bandung lainnya : Ekspedisi Bandung bireun Ekspedisi Bandung bitung Ekspedisi Bandung blang kejeren Ekspedisi Bandung blang pidie Ekspedisi Bandung blitar Ekspedisi Bandung blora Ekspedisi Bandung bobong Ekspedisi Bandung bojonegoro Ekspedisi Bandung bombana Ekspedisi Bandung bondowoso Ekspedisi Bandung bone Ekspedisi Bandung bontang Ekspedisi Bandung boroko Ekspedisi Bandung borong Ekspedisi Bandung boyolali
How to purchase lab products?
Laboratories, infirmaries, seminaries, the institution of higher education, and numerous other administrations are looking for first-class laboratory products. The marketplace is big, the quantity of Laboratory Product Manufacturers is big and does not continuously know who to select. Laboratory Apparatus Kinds The quantity of laboratory apparatus produces is very big, from kilns, incubators to minor but vital gaging tools. Amongst the kinds of produces obtainable in the laboratory are incubators, shakers, vacuity rotisseries, extractors, spectrophotometers, optical microscopes, and more. In footings of charges, too, each group and class has diverse produce at diverse capacity stages, each of which has a diverse expense. Correct acquisition of laboratory products Many businesses are beholding for laboratory products and occasionally look at the value, here's where the difficulty instigates. Beforehand you look at the value, principal of all, look at precisely what you requisite, what you are beholding for. Who is the Laboratory Product Manufacturers of a similar product, what you acquire in the same creation, all these considerations are very imperative in the purchasing process. Guarantee and overhaul on the produce When you want to purchase merchandise, you need to know what provision you will obtain about the merchandise and its guarantee. The lab produces are often costly products and we want to know that there are specialized and dependable Laboratory Product Dealers from whom we are purchasing. Here are some tips to reflect on while making a purchase. 1. Classify the Foremost Characteristics and Stipulations Distinguish how much worth a portion of the assumed product is probable to enhance to your lab and how its purposes. Examine the methodological stipulations to know the quantity of material they can check and how firm they do it. Associating the description and characteristics from several produces affects your selection of diverse apparatus with auspicious specs but destined for similar work. 2. Stare for Easy-To-Use Apparatus Purchasing a lab product from Laboratory Product Dealers, such as molecular spectroscopy, will streamline your effort. The solitary motive for acquiring apparatus is to make your work calmer and wieldy. Apparatus that has many Traits frequently make your work too complex. 3. Continuously Effort within Your Financial plan Be exact on how much you will require to purchase a part of the assumed lab apparatus before you start spending. Take into deliberation the obtainability of assets and the kind of services you offer. Contingent on the magnitude of your laboratory and stage of facilities, you can always find reasonable apparatus available with Laboratory Product Dealers. 4. Gaze at the Class and Makes Investigation on desirable makes and facsimiles. You must know all the information accessible in the market about exact lab amenities to guarantee the excellence you are expected to get when you purchase them. Apparatus from Laboratory Product Manufacturers who have been in the marketplace for an elongated time inclines to be of high class and are typically obtainable in big laboratories. Though, with the developing skill, you can find new makes and replicas that are also decent. 5. Investigate On the Past Of The Apparatus The best method to find the trajectory accounts of an individual gadget is to tête-à-tête to the Laboratory Product Suppliers. Safeguard there are no recognized glitches related to the apparatus if you are forecasting on purchasing recycled tools. If conceivable, ask for upkeep records if you are purchasing unswervingly from the laboratory to safeguard the apparatus are well preserved. Defining how much cash you are likely to expend over the next ages founded on whether you purchase recycled or new apparatus will help you make the correct conclusion. The most significant thing is to ensure if Laboratory Product Manufacturers store the classes of gears that will aid you to recover the excellence of facilities obtainable in your workroom. If you want to purchase the best Laboratory Products, look for trusted Laboratory Product Suppliers on Ozahub.
X-linked hypophosphatemia Market by DelveInsight
X-linked hypophosphatemia is a hereditary renal phosphate-wasting disorder characterized by hypophosphatemia, rickets and/or osteomalacia, and diminished growth. Phosphate levels are low because phosphate is abnormally processed in the kidneys, which causes a loss of phosphate in the urine (phosphate wasting) and leads to soft, weak bones (rickets). XLH is usually diagnosed in childhood. Features include bowed or bent legs, short stature, bone pain, and severe dental pain. XLH is the most common form of hereditary hypophosphatemic rickets. DelveInsight's "X Linked Hypophosphatemia Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the X Linked Hypophosphatemia, historical and forecasted epidemiology as well as the X Linked Hypophosphatemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Some facts of X Linked Hypophosphatemia Market Report are: · According to study conducted by He ́le`ne et al., titled “Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms”, the estimated prevalence of X-linked hypophosphatemia was 4.8 per 100,000. · As per Endocrine Society, the Food and Drug Administration (FDA) estimates that XLH affects about 3,000 children and 12,000 adults in the United States · According to Phosphodiabetes E.V. Netzwerk Information Austausch, estimates that X-linked hypophosphatemia (XLH) is the most common form of vitamin D-resistant rickets and, with a prevalence of 4.8 cases per 100,000 individuals, is considered a rare disease. · The study by Riancho et al., titled “Osteomalacia and rickets” estimates that the prevalence of Hypophosphatemic rickets linked to the X chromosome due to a mutation in the PHEX gene is around 5 per 100,000. View Report: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market Request for Sample Report: https://www.delveinsight.com/sample-request/x-linked-hypophosphatemia-market Scope of X Linked Hypophosphatemia Market Report are: The report covers the descriptive overview of X Linked Hypophosphatemia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies Comprehensive insight has been provided into the X Linked Hypophosphatemia epidemiology and treatment in the 7MM Additionally, an all-inclusive account of both the current and emerging therapies for X Linked Hypophosphatemia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape A detailed review of X Linked Hypophosphatemia market; historical and forecasted is included in the report, covering drug outreach in the 7MM The report provides an edge while developing business strategies, by understanding trends shaping and driving the global X Linked Hypophosphatemia market View Report: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market Some of X Linked Hypophosphatemia Companies are: · Ultragenyx · Validus Pharmaceuticals · Prospec-Tany Technogene Ltd · Merck KGaA · Zeria Pharmaceutical Co., Ltd · Smith & Nephew · Narang Medical Limited · Eli Lilly and Company · F. Hoffmann-La Roche Ltd · And Many Others View Report: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market Request for Sample Report: https://www.delveinsight.com/sample-request/x-linked-hypophosphatemia-market X Linked Hypophosphatemia Therapies are: · Burosumab · Crysvita · And Many Others Table of Contents: 1. Key Insights 2. Executive Summary of X Linked Hypophosphatemia 3. Competitive Intelligence Analysis for X Linked Hypophosphatemia 4. X Linked Hypophosphatemia: Market Overview at a Glance 4.1. X Linked Hypophosphatemia Total Market Share (%) Distribution in 2018 4.2. X Linked Hypophosphatemia Total Market Share (%) Distribution in 2030 5. X Linked Hypophosphatemia: Disease Background and Overview 6. Patient Journey 7. X Linked Hypophosphatemia Epidemiology and Patient Population 8. Treatment Algorithm, Current Treatment, and Medical Practices 8.1. X Linked Hypophosphatemia Treatment and Management 8.2. X Linked Hypophosphatemia Treatment Algorithm 9. Unmet Needs 10. Key Endpoints of X Linked Hypophosphatemia Treatment 11. Marketed Products List to be continued in report 12. Emerging Therapies List to be continued in report 13. X Linked Hypophosphatemia: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Market Outlook 16. Access and Reimbursement Overview of X Linked Hypophosphatemia 17. KOL Views 18. Market Drivers 19. Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer Some of Newly Launched Report: · Defibrillators market · Advanced Wound Care market · Coronary Stents market · Neuromodulation Devices market · Neurostimulation Devices market · Hernia repair devices market · Hyperhidrosis market About Delveinsight: DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems. Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: info@delveinsight.com Phone: +19193216187 City: Albany State: New York Country: United States Website: https://www.delveinsight.com/
How COVID-19 Impacted on Green Steel in Chemicals & Materials Industry ?
COVID-19 Impact on Green Steel in Chemicals and Materials Industry The COVID-19 pandemic has influenced the whole planet with its major impacts on the economy and businesses across the globe. The COVID-19 spread worldwide in unprecedented ways due to its high infectious and contagious nature and lack of availability of its vaccine. As a result, the greatest medical challenge in the 21st century is yet to be faced by physicians worldwide. Though the emergence of the virus can be traced back to Asia, many European countries along with the U.S. have been struck massively by the pandemic. The virus has spread across all regions ranging from North America, Europe, Asia-Pacific, Middle East, and Africa up to South America. The COVID-19 has been declared as a pandemic by World Health Organization (WHO) due to its increased spread across the globe. After the declaration of the pandemic, various countries announced the complete lockdown such as India, China, and other Asian countries to decrease its spread. According to the latest situation report by World Health Organization (WHO) stated 175 million cases of Corona have been reported globally and 4 million patients are dead due to the coronavirus. On a slightly positive note, a total of 158 million people have recovered and a total of 2 million vaccine doses have been administered as well. Steel production necessitates the removal of oxygen from iron ore to generate pure iron metal. This is done in traditional steel-making using coal or natural gas in a CO2 emitting process. In the manufacture of green steel, hydrogen derived from renewable energy substitute’s fossil fuels. COVID-19 has adversely affected the demand of the global green steel market, particularly, in the power and energy sector. Pandemic has also affected the import and export of steel products across all the regions which have resulted in the decline in the demand for green steel. The demand for green steel has declined approximately by 12%-14% in the COVID-19 period. The COVID-19 has unbiasedly affected all sectors due to which the mandate of the several products in the global as well as in the domestic market has affected. The prevailing green steel demand conditions in the majority of developing nations demonstrate that steel consumption has declined in the pandemic situation. Several large industries that are engaged in the manufacturing of green steel have faced several challenges. However, the post- pandemic scenario has already accelerated both technological advancement and the green transition. AFTERMATH OF COVID-19 AND GOVERNMENT INITIATIVE TO BOOST THE GLOBAL Green Steel MARKET China, the world's largest steel producer, has pledged to become carbon neutral by 2060, generating almost half of the world's supply. About 15% of the country's carbon emissions come from the steel industry. Post COVID-19, developing economies, such as China is expected to move more rapidly towards normalization of economic activity for the different sectors. This will increase the demand for green steel products and will increases the import of green steel. With the stringent government regulations, particularly, in the field of infrastructural, the demand for green steel products such as hot-rolled sheets and cold-rolled sheets would subsequently increase. Automobile manufacturers are heavily investing funds in the market. With the increase in the demand for modern electric vehicles, the demand for green steel is set to rise in the global market. STRATEGIC DECISIONS FOR MANUFACTURERS AFTER COVID-19 TO GAIN COMPETITIVE MARKET SHARE Pre-pandemic manufactures had financial stability; however, COVID-19 had forced the manufacturers into extreme slumps. The effects of the pandemic will largely affect small and medium businesses. Green steel is extensively used in the manufacturing of electric motors and components which are brought to application in electric appliances. During the COVID-19, manufacturing of the heavy equipment has tumbled down which result in a fall in the demand for green steel in motors application. During the pandemic, several heavy electrical equipment manufacturers have shut down production for more than 6 months which have had a bad impact on the demand for the green steel market. IMPACT ON PRICE The steel industry is also playing a crucial role in the green steel market since tons of steel and other metals are used in the manufacturing of green steel. The pandemic of COVID-19 has also impacted the demand for steel products in all the regions. In the U.S., steel mills have to adjust their production activities to avoid rising inventories and declining prices of steel products which result in lower revenue generation. As the steel demand is declining, integrated steelmakers in U.S. steel manufacture have decided to idle blast furnaces and cut production of steel. IMPACT ON DEMAND During the COVID-19, manufacturing of the heavy green equipment has tumbled down which resulted in the declined demand for greens steel. Several types of components are used in the transformers which have different flux density that help to lower the wastage of the energy during transmission, however, the demand of the different size of transformers have collapsed. During the pandemic, several green equipment manufacturers have shut down production for an indefinite period, which has an adverse impact on the demand of green steel market IMPACT ON SUPPLY CHAIN The power and energy industry is heavily relying on Supply Chain Management (SCM). Improvement in the supply chain has always been demanded by the manufacturers and end-users. The COVID-19, which led to the abrupt halt of the transportation sector, indirectly affected the supply chain for the green steel market. Manufacturers had to bear the storage cost as well as had to face the consequences for the late conveyances. The delivery of raw goods was adjourned or annulled, which resulted in the rise of the cost to the end-users. The import-export of the final product was also severely wedged, hindering the completion of major projects, resulting in increased costs. CONCLUSION Pandemic has taken a toll on every aspect of life, including the global economy. With the significant downfalls in many sectors, a collaborative effort of government, industry players, and consumers can win the fight against COVID-19. It continues to inflict the world with appalling economic and social dilemmas, capable enough to leave severe backlash on the economy for the next several years. The first wave had already inflicted severe blows to the population as well as the economy. The currently experiencing the second wave is expected to be more disastrous not only to the masses but also to CnM markets. The COVID-19 crisis has created a pandemic situation widely, which affected the growth of the overall steel industry. The demand in the energy and power, building and construction, automotive activities have withered down globally. The nationwide lockdown across the globe for all the manufacturing units, construction activities, and others, resulted in lower demand for green steel products, which eventually, lead to a huge loss for manufactures. The manufacturers of green steel components and equipment had to abruptly halt the production which had an impact on the supply chain. Growing demand for carbon-neutral industrial products is boosting the demand for green steel. The fluctuation in the price of steel has also impacted the manufacturing of green steel. Progressive demand for electricity and power as well as the launch of green vehicles will increase the demand for green steel in coming years.